Toboroz
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
NCT07022678· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Toboroz
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
NCT07466316· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Toboroz
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Toboroz
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
NCT06647953· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Toboroz
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Fut, nem toboroz
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
NCT04203316· 2. fázis· Children's Oncology Group· Forrás
Toboroz
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Florence Choo (principal investigator)
Toboroz
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Fut, nem toboroz
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
NCT04939597· 3. fázis· Children's Oncology Group· Forrás
Toboroz
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241· 1/2. fázis· PedAL BCU, LLC· Forrás
Contact: Florence Choo (principal investigator)
Toboroz
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NCT05235165· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Fut, nem toboroz
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT04994132· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
NCT04385277· 2. fázis· Children's Oncology Group· Forrás
Toboroz
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Florence Choo (principal investigator)
Toboroz
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04322318· 2. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Fut, nem toboroz
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04284774· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
NCT04195399· 2. fázis· Children's Oncology Group· Forrás
Toboroz
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Fut, nem toboroz
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
NCT03817398· 2. fázis· Children's Oncology Group· Forrás
Toboroz
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Fut, nem toboroz
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
NCT03834961· 2. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
NCT03794349· 2. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
NCT03595124· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03698994· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
NCT03190915· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
NCT03210714· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03533582· 3. fázis· Children's Oncology Group· Forrás
Toboroz
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT03126916· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Fut, nem toboroz
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
NCT02724579· 2. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCT03213704· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628· 2. fázis· Children's Oncology Group· Forrás
Toboroz
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181· 3. fázis· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Fut, nem toboroz
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT02867592· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT02521493· 3. fázis· Children's Oncology Group· Forrás
Toboroz
Project: Every Child for Younger Patients With Cancer
NCT02402244· Children's Oncology Group· Forrás
Contact: Florence Choo (principal investigator)
Fut, nem toboroz
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
NCT02339740· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
NCT02166463· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT02306161· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02112916· 3. fázis· National Cancer Institute (NCI)· Forrás
Showing 50 of 53.